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OBJECTIVE — To describe the sensitivity, speciﬁcity, positive predictive value, and negative
predictive value of vibration perception threshold (VPT) testing in subjects with type 1 diabetes
relative to gold standard assessments of peripheral neuropathy.
RESEARCH DESIGN AND METHODS — VPT was determined in 1,177 adults with
type 1 diabetes 13–14 years after participating in a study of intensive (INT) versus conventional
(CONV) diabetes treatment. Abnormal VPT was deﬁned by values exceeding 2.5 SD above
age-speciﬁc normal values. Signs and symptoms of peripheral neuropathy were assessed and
electrodiagnostic studies were performed to establish deﬁnite clinical neuropathy, abnormal
nerve conduction, and conﬁrmed clinical neuropathy (the presence of both deﬁnite clinical
neuropathy and abnormal nerve conduction).
RESULTS — Thirty-seven percent of subjects had deﬁnite clinical neuropathy, 61% had
abnormal nerve conduction, and 30% had conﬁrmed clinical neuropathy. Abnormal VPT was
more common among former CONV than among INT subjects (64 vs. 57%, P  0.05) and was
associated with older age. VPT was a sensitive measure of conﬁrmed clinical neuropathy (87%)
and of deﬁnite clinical neuropathy (80%) and a speciﬁc measure of abnormal nerve conduction
(62%). Higher VPT cut points improved test sensitivity and lower cut points improved speci-
ﬁcity. Areas under the receiver operating characteristic curves ranged from 0.71–0.83 and were
higher for older than for younger subjects and highest for those with conﬁrmed clinical
neuropathy.
CONCLUSIONS — VPTwasasensitivemeasureofperipheralneuropathy.Futureresearch-
ersmaychoosetoselectVPTcutpointsfordeﬁningabnormalitybasedonthepopulationstudied
and clinical outcome of interest.
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I
n the Diabetes Control and Complica-
tions Trial (DCCT), distal symmetrical
peripheralneuropathy(DSPN)wasde-
ﬁned categorically on the basis of clinical
ﬁndings and electrodiagnostic (nerve
conduction) studies (1–3). At the conclu-
sionoftheDCCT,subjectswereinvitedto
participate in the Epidemiology of Diabe-
tes Interventions and Complications
(EDIC) study, a long-term observational
follow-up of the DCCT cohort (4). In the
EDIC study, DSPN was assessed annually
using the Michigan Neuropathy Screen-
ing Instrument (4,5). Beginning in 2007,
during the 13th and 14th years of EDIC
studyfollow-up(EDIC13/14),theassess-
ments of DSPN performed during DCCT
wererepeated.Inkeepingwithconsensus
recommendations to include quantitative
sensorytestinginthediagnosisofdiabetic
neuropathy (6,7), vibration perception
threshold (VPT) testing was added to the
battery of neurological assessments per-
formed at EDIC 13/14. Herein we de-
scribe VPT studies among EDIC study
subjects 13–14 years after the conclusion
of the DCCT and evaluate the perfor-
manceofVPTasastand-alonemethodfor
identifying DSPN relative to gold stan-
dard assessments involving neurologists’
examinations and electrodiagnostic
studies.
RESEARCH DESIGN AND
METHODS— At baseline, the DCCT
studied 1,441 subjects aged between 13
and39yearswithtype1diabetesfor1–15
years who were generally in good health.
Subjects were randomly assigned to in-
tensive (INT) or conventional (CONV)
therapy and were followed for a mean of
6.5 years (1). The EDIC study enrolled
1,375 of the surviving DCCT subjects in
1994 (687 INT and 688 CONV). During
EDIC13/14,VPTstudieswereperformed
on 624 (94%) of former INT and 601
(91%) of former CONV subjects (4).
Characteristics of subjects with VPT as-
sessment did not differ from those of sub-
jects who did not have VPT assessment
performed (data not shown). Concurrent
DSPN assessments were performed on
1,177 subjects.
VPT
VPT was assessed using the Vibratron II
(Physitemp Instruments, Clifton, NJ).
The device produces vibration ampli-
tudes from 0.005–200 microns, ex-
pressed as vibration units (0.005
microns  0.1 vibration unit; 200 mi-
crons  20.0 vibration units), with a
higher vibration unit value indicating
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dysfunction. A forced-choice algorithm
was used to determine VPT at the domi-
nant index ﬁnger and dominant great toe.
The examiner controlled which of two
metal posts (labeled A and B) was vibrat-
ing and controlled the vibration units us-
ing a predetermined algorithm. The
subject placed his or her digit (ﬁnger or
toe) ﬁrst on post A and then on post B
using light pressure for about 1 s and was
asked to state which was vibrating. Sub-
jects were encouraged to guess if uncer-
tain and were not told if they were correct
or incorrect. Subjects were positioned to
prevent them from seeing the device set-
tings. Vibration intensity was increased
by 10% after incorrect responses and was
decreasedby10%aftercorrectresponses.
Stimuli at vibration units of 1.0 were
repeated before increasing or decreasing
the vibration intensity. The test was
stopped when the subject made ﬁve er-
rors over a minimum of 18 trials. Vibra-
tion units corresponding to the subject’s
ﬁrst ﬁve errors and the ﬁve lowest cor-
rectly identiﬁed vibration units were rank
ordered; the highest and lowest of these
10 were discarded. The average of the re-
maining eight values was recorded as the
VPT.Duringacentraltrainingsession,the
study coordinator or research nurse from
each EDIC study site was trained and was
required to submit at least two VPT tests
on non-EDIC study subjects to demon-
strate competency in test administration
and scoring.
Ninety-four subjects, two to six from
each clinical site, were randomly selected
for repeat VPT testing of the great toe on
thesamedayandbythesameexamineras
a measure of test reproducibility. Exam-
iners were instructed to wait at least 30
min between tests. In the interval, sub-
jects re-wore any footwear worn before
the primary test (8).
VPT results are expressed both as
continuous and categorical variables us-
ing age-speciﬁc normal values provided
by Physitemp Instruments (9). Values
within 2.5 SD of the age-speciﬁc mean
werecategorizedasnormal,andthoseex-
ceeding 2.5 SD were categorized as
abnormal.
Deﬁnition of DSPN in DCCT and
EDIC
Board-certiﬁed neurologists and electro-
myographers were identiﬁed, trained,
and certiﬁed in the EDIC study to con-
duct neurological evaluations and elect-
rodiagnostic studies using the protocol
for the DCCT (1–3). Three analytic deﬁ-
nitions were used in the DCCT and sub-
sequently in the EDIC study to deﬁne
DSPN. The ﬁrst, deﬁnite clinical neurop-
athy, indicates the presence of symptoms
and signs consistent with DSPN based on
history and physical examination by a
board-certiﬁed neurologist. The second,
abnormal nerve conduction, represents
one or more abnormal nerve conduction
results (amplitude, conduction velocity,
orFresponselatency)intwodifferentpe-
ripheral nerves among the median (sen-
sory or motor), peroneal motor, or sural
sensory studies. Finally, conﬁrmed clini-
cal neuropathy was deﬁned as the pres-
ence of both deﬁnite clinical neuropathy
and abnormal nerve conduction (1–3).
Statistical analysis
Groups were compared using Wilcoxon
rank sum tests for ordinal or continuous
variables and contingency 
2 tests for cat-
egorical variables. The performance of
VPT in predicting deﬁnite clinical neu-
ropathy,abnormalnerveconduction,and
conﬁrmed clinical neuropathy was as-
sessed by determining sensitivity, speci-
ﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and the
Cohen  (10) in the full cohort and sepa-
rately for those aged 36–50 and 51–65
years.Sensitivityistheprobabilityofhav-
ing an abnormal VPT test in the presence
of neuropathy. Speciﬁcity is the probabil-
ity of having a normal VPT test in the
absenceofneuropathy.PPVisthepropor-
tion of subjects with neuropathy among
those with abnormal VPT test results, re-
ﬂecting both the sensitivity of the test and
the prevalence of the condition in the
population.NPVistheproportionofsub-
jects without neuropathy among those
withnormalVPTtests.TheCohenmea-
sures agreement between two methods. 
measures the percentage of data values in
the main diagonal of a 2  2 table and
then adjusts these values for the amount
of agreement that could be expected due
tochancealone.Perfectagreementresults
in the maximum value for  of 1.0, values
between0.20and0.39indicatefairagree-
ment, values between 0.4 and 0.59 indi-
cate moderate agreement, and values
0.6 indicate good agreement. Receiver
operating characteristic (ROC) curves
show the relationship between the true-
positive ratio (sensitivity) and false-
positiveratio(1speciﬁcity)ofatestand
canbeusedtodeﬁnecutpointstoidentify
abnormal test results (11). Areas under
the ROC curve (AUC) measure the per-
formance of a test in predicting the out-
come of interest. Generally, AUC values
of0.5indicatethatatestperformsnobet-
ter than chance, values between 0.70 and
0.79 indicate fair performance, values be-
tween 0.80 and 0.89 indicate good per-
formance, and values 0.9 indicate
excellent test performance.
RESULTS— Characteristics of the
1,177 participants with both DSPN and
VPT assessment are shown in Table 1.
DSPN was more prevalent among former
CONV than among former INT partici-
pants (P  0.01) using all three analytic
deﬁnitions. DSPN prevalence among all
participants was highest when deﬁned by
abnormal nerve conduction (61%). Deﬁ-
nite clinical neuropathy was present in
37% of subjects and conﬁrmed clinical
neuropathy in 30% of subjects.
Subjects selected for repeat VPT test-
Table 1—Characteristics of subjects evaluated for VPT in EDIC 13/14
Characteristic Total cohort INT CONV
n 1,177 599 578
Age (years) 47  74 8  74 7  7*
Men (%) 622 (53) 307 (51) 315 (55)
Duration of diabetes (years) 26  52 6  52 6  5
A1C (%) 7.8  1.2 7.8  1.2 7.8  1.2
Height (cm) 172  10 171  9 173  10
BMI (kg/m
2) 28.2  5.0 28.4  5.2 28.0  4.7
Lower extremity ulcers (%) 90 (8) 37 (6) 53 (9)
Deﬁnite clinical neuropathy (%) 438 (37) 201 (34) 237 (41)†
Abnormal nerve conduction (%) 722 (61) 324 (54) 398 (69)†
Conﬁrmed clinical neuropathy (%)‡ 353 (30) 151 (25) 202 (35)†
Data are means  SD or n (%). Data are presented for same year in which the VPT test was performed. *P 
0.05; †P  0.01 for treatment group differences by the Wilcoxon rank sum test or contingency 
2 test.
‡Presence of signs and symptoms consistent with distal symmetrical polyneuropathy with abnormal elect-
rodiagnostic tests in at least two of three nerves tested.
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cohort with respect to age (47.3  7.3
years), sex (52% male), diabetes duration
(24.8  4.3 years), and frequency of con-
ﬁrmed clinical neuropathy (40%) and
were equally distributed between treat-
ment groups (n  50 INT; n  44
CONV). Eighty-three subjects had repeat
testing. The mean primary and repeat test
scores did not differ (3.8  2.7 vs. 3.9 
2.8 vibration units, P  0.38). The calcu-
lated test-retest coefﬁcient of reliability
was 0.85.
Mean VPT was higher at both the
great toe and index ﬁnger among former
CONVversusINTsubjects(4.03vs.3.53,
P  0.01 at the great toe; 1.11 vs. 0.99,
P  0.01 at the index ﬁnger) (Table 2).
VPT was abnormal at the great toe in a
majority(61%)ofsubjectsbutwasabnor-
mal at the index ﬁnger in only 6% of sub-
jects. VPT abnormalities were more
prevalent among former CONV than
among former INT subjects at both the
toe and ﬁnger. Older age, regardless of
former treatment group, was associated
with higher mean VPT and greater preva-
lence of abnormal VPT (Table 2). Mean
VPT values were higher at both the index
ﬁnger (1.26  0.67 vs. 1.03  0.49, P 
0.001) and great toe (5.86  3.21 vs.
3.62  2.20, P  0.001) among subjects
reporting a lower extremity ulcer during
the EDIC study compared with subjects
with no reported lower extremity ulcers.
VPT was a sensitive predictor of all
three DSPN outcome measures (Table 3),
with the highest sensitivity noted for con-
ﬁrmed clinical neuropathy (87%). The
sensitivity of VPT to predict deﬁnite clin-
ical neuropathy and abnormal nerve con-
duction was 80 and 75%, respectively.
For all three outcomes, sensitivity in-
creased with age. Speciﬁcity of VPT was
highest for abnormal nerve conduction
(62%) and lowest for deﬁnite (51%) or
conﬁrmedclinicalneuropathy(51%)(Ta-
ble 3). For all outcome measures, speci-
ﬁcity decreased with age.
ThePPVofVPTwashigherforabnor-
malnerveconduction(76%)thanfordef-
inite (49%) or conﬁrmed clinical
neuropathy(43%)andincreasedwithage
(Table 3). The NPV of VPT was higher for
conﬁrmed (90%) and deﬁnite clinical
neuropathy (81%) than for abnormal
nerve conduction (61%) and did not vary
substantially by age (Table 3).  values
indicated at least fair agreement between
VPT and all three outcome measures and
were higher (indicating better agreement
between VPT and the neurological out-
come measures) in older participants.
ROC curves were generated to plot
the performance of great toe VPT against
allthreeDSPNoutcomemeasures.Figure
1 shows the relationship between the
true-positive ratio (sensitivity) and the
false-positive ratio (1  speciﬁcity) for
various VPT values to predict deﬁnite
clinical neuropathy (Fig. 1A), abnormal
nerve conduction (Fig. 1B), and con-
ﬁrmed clinical neuropathy (Fig. 1C). For
the full cohort, VPT values that provided
80% sensitivity were 4.30, 3.55, and
4.29 for deﬁnite clinical neuropathy, ab-
normal nerve conduction, and conﬁrmed
clinical neuropathy, respectively. VPT
values that provided 80% speciﬁcity
were 2.61 for deﬁnite clinical neuropa-
thy, 2.34 for abnormal nerve conduction,
and 3.31 for conﬁrmed clinical neuropa-
thy. AUC ranged from 0.71–0.83, indi-
cating fair to good performance and were
highest for conﬁrmed clinical neuropa-
thy.SeparateROCcurveswerecreatedfor
subjects aged 36–50 (Fig. 1D–F) and
51–65 years (Fig. 1G–I) (together ac-
counting for 95% of the total cohort).
AUC was higher for older participants:
Table 2—VPT results for subjects evaluated in EDIC 13/14 by treatment group and age category
Characteristic Total cohort
Treatment group Age categories
INT CONV 35 years 36–50 years 51–65 years
n 1,177 599 578 59 693 425
VPT great toe 3.78  2.35 3.53  2.19 4.03  2.47† 2.38  1.61 3.44  1.97 4.53  2.75†
Abnormal 710 (61) 341 (57) 369 (64)* 20 (34) 401 (58) 289 (69)†
VPT index ﬁnger 1.05  0.51 0.99  0.42 1.11  0.58† 0.96  0.42 1.00  0.47 1.13  0.58†
Abnormal 71 (6) 24 (4) 47 (8)† 2 (3) 41 (6) 28 (7)
Data are means  SD vibration units or n (%). *P  0.05; †P  0.01for treatment group or age-group differences by the Wilcoxon rank sum test or contingency 
2
test.
Table 3—Performance of VPT testing on the great toe
n* Sensitivity Speciﬁcity PPV NPV % correct 
Deﬁnite clinical neuropathy
Total cohort 1,170 80 (76–84) 51 (47–54) 49 81 62 0.271
Aged 36–50 years 691 75 (69–81) 50 (46–55) 42 81 58 0.208
Aged 51–65 years 420 87 (82–92) 47 (41–54) 59 80 66 0.330
Abnormal nerve conduction
Total cohort 1,170 75 (72–78) 62 (58–67) 76 61 70 0.271
Aged 36–50 years 691 72 (68–77) 63 (57–68) 74 61 68 0.350
Aged 51–65 years 420 81 (76–85) 57 (48–65) 80 58 73 0.377
Conﬁrmed clinical neuropathy
Total cohort 1,170 87 (84–91) 51 (47–54) 43 90 62 0.296
Aged 36–50 years 691 84 (78–89) 51 (46–55) 37 90 59 0.241
Aged 51–65 years 420 93 (89–97) 47 (41–53) 53 91 65 0.348
Data are % (95% CI) unless otherwise indicated. *n  7 subjects who are missing a great toe measurement.
Martin and Associates
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athy, 0.78 vs. 0.75 for abnormal nerve
conduction, and 0.83 vs. 0.76 for con-
ﬁrmed clinical neuropathy.
CONCLUSIONS — We determined
VPT and the prevalence of abnormal VPT
in 1,177 subjects with type 1 diabetes
during the 13th or 14th year of their par-
ticipation in the EDIC study. VPT was a
reliable measure of DSPN and a sensitive
and speciﬁc measure of deﬁnite clinical
neuropathy, abnormal nerve conduction,
and conﬁrmed clinical neuropathy in this
large cohort of patients with long-
standing type 1 diabetes and a high prev-
alence of DSPN.
VPTtestsattheindexﬁngerandgreat
toewereperformedconcurrentlywithde-
tailed neurological assessments and
electrophysiologicstudies.Toensureuni-
formity in test administration, all EDIC
study sites used the same devices and had
centralized training. VPT testing was per-
formed on the same day as the subject’s
neurological assessment and electrophys-
iological studies to minimize temporal
variability when results were compared.
ToverifyVPTtestreproducibility,weper-
formed repeated, same day testing in a
randomly selected subset of subjects and
determined that the test-retest coefﬁcient
of reliability was good (0.85).
Figure 1—ROC curves for the accuracy of VPT testing at the great toe for predicting deﬁnite clinical neuropathy (A), abnormal nerve conduction
(B), and conﬁrmed clinical neuropathy (C) in all subjects. The ROC curves shown in D–F are for the accuracy of VPT in predicting deﬁnite clinical
neuropathy (D), abnormal nerve conduction (E), and conﬁrmed clinical neuropathy (F) among subjects aged 35–50 years, whereas G–I show ROC
curvesfortheaccuracyofVPTtestingatthegreattoeforpredictingdeﬁniteclinicalneuropathy(G),abnormalnerveconduction(H),andconﬁrmed
clinical neuropathy (I) for subjects aged 51–65 years. For each ROC curve, the VPT value corresponding to each decile of 1  speciﬁcity is shown.
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cally meaningful information about large
nerve ﬁber dysfunction in diabetes. The
neurologicalimpairmentsassociatedwith
large ﬁber neuropathy account for 	80%
of the morbidity associated with DSPN
(12). Abnormal VPT values have been
showntopredictthelong-termcomplica-
tions of ulceration and amputation (13)
andhavebeenassociatedwithfootulcers,
gangrene, amputation and lower extrem-
ity bypass, or angioplasty in type 1 diabe-
tes (14). Common criticisms of VPT
testing are that it is not sufﬁciently spe-
ciﬁc to large ﬁber or even to peripheral
nerve dysfunction, that the results are in-
ﬂuencedbysubjectattentiveness,motiva-
tion, and fatigue (15–18), that
reproducibility may vary in nondiabetic
and diabetic populations, and that results
may vary depending on the device used
(15,18).VPTtestinghastheadvantagesof
being simple, quick to perform, painless,
and generally well tolerated. VPT results
are not signiﬁcantly affected by the pres-
ence of foot callus or by limb temperature
(15). These advantages and the availabil-
ity of standardized testing algorithms
make VPT an attractive option for DSPN
assessment in research settings.
The higher prevalence of abnormal
VPT observed at the great toe versus the
index ﬁnger in our study was not unex-
pected, given the characteristic length-
dependent(stockingdistribution)pattern
of DSPN. Likewise, higher mean VPT val-
ues and increased prevalence of abnor-
malities among older subjects is not
wholly unexpected, given the known ef-
fects of aging on peripheral nerve func-
tion. The higher prevalence of abnormal
VPT values in former CONV than in
formerINTparticipantsisconsistentwith
the higher prevalence of deﬁnite clinical
neuropathy, of abnormal nerve conduc-
Figure 1—Continued.
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thy in the CONV group as reported
previously (19).
Sensitivity and speciﬁcity, PPV, NPV,
and ROC curves relating VPT at the great
toe to each of the analytic deﬁnitions of
neuropathy used in the EDIC study were
used to evaluate the utility of VPT to pre-
dict DSPN. VPT at the index ﬁnger was
not used because 8% of all subjects had
abnormal VPT at the ﬁnger. As a practical
consideration,inclusionoftheVPTtestat
the ﬁnger, conducted before testing at the
toe, gives the subject an opportunity to
become familiar with the test procedure
and gives the examiner an opportunity to
assessthesubject’sattentivenessandwill-
ingness to undergo testing.
We show that VPT at the great toe is a
sensitivepredictorofbothdeﬁniteclinical
neuropathy and conﬁrmed clinical neu-
ropathy. Because sensory examination of
large nerve ﬁbers (e.g., vibration and po-
sition sense) is a components of the neu-
rologists’ evaluation, this ﬁnding is not
unexpected. VPT was a less sensitive in-
dicator of abnormal nerve conduction,
probably reﬂecting inclusion of upper ex-
tremity nerves in the deﬁnition of abnor-
mal nerve conduction, and identiﬁcation
of subclinical neuropathy as mild abnor-
malities of physiological function deter-
mined by electrodiagnostic criteria but
without clinically discernible signs or re-
ported symptoms as we have previously
reported (20). Speciﬁcity of VPT was
greatest for abnormal nerve conduction.
Overall, the sensitivities and speciﬁcities
obtained in our study compare favorably
to those of others who have reported sen-
sitivities between 58 and 84% and speci-
ﬁcities between 61 and 86% for VPT (21–
24) measured by a variety of test devices
and test methods.
The ROC curves demonstrate the
clear tradeoff between sensitivity and
speciﬁcity when VPT is used as a predic-
tor of DSPN. For example, to attain 90%
sensitivityforVPTtestingasapredictorof
conﬁrmed clinical neuropathy, the cut
point to determine abnormal VPT would
be 5.5. That would, however, provide a
speciﬁcity of only 40% (Fig. 1C). Opti-
mizing speciﬁcity at 90% sets the cut
point at 2.2 but limits sensitivity to
40%. With use of the ROC curves, cut
pointscanbechosentooptimizesensitiv-
ityand/orspeciﬁcityaccordingtotheout-
come of interest and age-group under
study.TheAUCssuggestthatVPTperfor-
mance is fair to good, with VPT best at
predicting conﬁrmed clinical neuropathy
and with greater predictive value in older
age-groups (again, not unexpected given
the known effects of aging). With  as
another measure of agreement, VPT had
atleastfairagreementwithnerveconduc-
tion studies. Abnormal nerve conduction
was more prevalent than either deﬁnite
clinical neuropathy or conﬁrmed clinical
neuropathy; therefore, the PPV of VPT
was highest as a measure of abnormal
nerve conduction. NPV was higher for
conﬁrmed clinical neuropathy and deﬁ-
nite clinical neuropathy and lower for ab-
normal nerve conduction, reﬂecting the
lower prevalence of the conﬁrmed and
deﬁnite clinical neuropathy. Although
theseanalysesdonotaddresstheutilityof
VPTasameasureofdiseaseseverityorthe
ability of VPT to measure change in neu-
ropathystatusovertime,theymayinform
future investigations that use the same
methodology, providing appropriate
thresholds for determining the presence
of DSPN.
In general, VPT was best as an indica-
tor of conﬁrmed clinical neuropathy,
which was especially true among older
participants. VPT as measured in the
EDIC study may be useful in future stud-
ies of type 1 diabetes with cut points se-
lected to optimize sensitivity and
speciﬁcity, depending on both the char-
acteristics of the population studied and
the clinical outcome selected.
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